European Cannabis Insights 2026 Whitepaper

On 10 June 2026, Business of Cannabis and CB Club convened the European Cannabis Insights Summit in Berlin, bringing together the executives, clinicians and policy specialists shaping Europe's largest cannabis market. This whitepaper — the third industry report from Business of Cannabis, powered by Prohibition Partners — captures the summit's presentations, debates and data, alongside Prohibition Partners' underlying market intelligence. The report examines four European markets at four different stages of the same cycle: Germany maturing, the United Kingdom growing, Poland recovering and France preparing to open. Germany anchors the analysis: a ≈€1.15 billion market in 2026, projected to reach €1.4–1.6 billion by 2030, where a 176% import surge and a 46% fall in pharmacy prices are forcing structural questions about supply, quality enforcement and margin survival. Drawing on longitudinal patient data from Bloomwell, physician reimbursement data from Copeia, supply-chain economics from alephSana and Cannamedical, regulatory analysis from EUMCA and CannaVigia, clinical channel insight from CKM Group and Cannaleo Digital, and lessons from Sanity Group's Swiss adult-use pilot, the whitepaper maps demand, behaviour and policy across the continent — including the July 2026 removal of cannabis flower from German statutory reimbursement, which came into effect after the summit and is analysed in the report. For operators, investors and policymakers, the conclusion is direct: Europe's medical cannabis market has established its foundations. What gets built on top of them will be decided in the next two to three years.